APPENDIX

Targeted delivery of a phosphoinositide 3-kinase γ inhibitor to restore organ function in sepsis through dye-functionalized lipid nanocarriers

Authors Adrian T. Press^{1,2,3}, Petra Babic^{1,3}, Bianca Hoffmann⁴, Tina Müller^{1,3}, Wanling Foo¹, Walter Hauswald⁵, Jovana Benecke^{1,3}, Martina Beretta^{1,3}, Zoltán Cseresnyés⁴, Stephanie Hoeppener^{6,7}, Ivo Nischang^{6,7}, Sina M. Coldewey^{1,3,8}, Markus H. Gräler^{1,3}, Reinhard Bauer¹⁰, Falk Gonnert^{1,3}, Nikolaus Gaßler⁹, Reinhard Wetzker^{1,3}, Marc Thilo Figge^{2,4,11}, Ulrich S. Schubert^{3,6,7}, Michael Bauer^{1,3,6}

Affiliations

¹ Department of Anesthesiology and Intensive Care Medicine, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany

²Medical Faculty, Friedrich Schiller University Jena, Bachstr. 18, Jena, Germany

³ Center for Sepsis Control and Care, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany

⁴ Research Group Applied Systems Biology, Leibniz Institute for Natural Product Research and Infection Biology - Hans Knoell Institute, Jena, Germany

⁵ Leibniz Institute of Photonic Technology, Albert-Einstein-Straße 9, 07745 Jena, Germany

⁶ Jena Center for Soft Matter (JCSM), Friedrich Schiller University Jena, Philosophenweg 7, 07743 Jena, Germany

⁷ Laboratory of Organic and Macromolecular Chemistry (IOMC), Friedrich Schiller University Jena, Humboldtstrasse 10, 07743 Jena, Germany

⁸ Septomics Research Centre, Jena University Hospital, Jena, Germany

⁹ Institute of Molecular Cell Biology, Jena University Hospital, Jena, Germany

¹⁰ Section of Pathology, Institute of Forensic Medicine, Jena University Hospital, Am Klinikum 1, 07747 Jena, Germany

¹¹ Institute of Microbiology, Faculty of Biological Sciences, Friedrich Schiller University, Jena, Germany

Correspondence to michael.bauer@med.uni-jena.de

Table of Content

Appendix Figure S 1: Cryo-Transmission electron microscopy with size quantification of non-targeted Liposomal formulation
Appendix Figure S2: Analytical ultracentrifugation of AS605240 loaded liposomes4
Appendix Figure S3: Effects of targeted AS605240 delivery on the inflammatory response
Appendix Figure S4: Scheme on processing and analysis of multispectral optoacoustic tomography (MSOT) images for the quantification of liver function by indocyanine green (ICG) clearance
Appendix Figure S5: Effects of the non-targeted liposomal AS605240 formulation on survival in the peritoneal contamination and infection (PCI) sepsis model
Appendix Table S1: PI3Kγ expression in human tissue biopsies9
Appendix Table S2: Characterization of primary human hepatocyte donor pools (Lonza, Switzerland)10
Appendix Table S3: p-Value Tables for Figures 2 to 5 in the main manuscript and Appendix Figure S3 and S5



Appendix Figure S 1: Cryo-Transmission electron microscopy with size quantification of non-targeted Liposomal formulation.

Diameter as measured from **TEM images** (ImageJ). Median box-plot with 0.25;0.75 IQR; whiskers 0.95 percentile, violin-plots depict density. NT-Lipo 14 images = 847 liposomes, NT-LipoAS 15 images = 540 liposomes, T-Lipo 5 images = 184 liposomes, T-LipoAS 12 images = 503 liposomes



Appendix Figure S2: Analytical ultracentrifugation of AS605240 loaded liposomes.

Analytical ultracentrifugation was performed with different concentrations of liposomes. The optical density monitored the sedimentation at 496 nm. Data analysis was accomplished with the $ls - g^*(s)$ model in Sedfit (version 15.01b). The $ls - g^*(s)$ model represents a least-squares boundary analysis under the assumption of non-diffusing species and resolves the apparent differential distribution of sedimentation coefficients.

The decrease of liposomal concentration shifted the sedimentation coefficient distributions toward larger values (solid lines). Finally, sedimented liposomes were resuspended by shaking the ultracentrifuge cells, then another sedimentation velocity analysis (dotted lines). Again, very similar results were observed at all concentrations, indicating the stability of liposomes during sedimentation and after resuspension leading to the observation of identical populations.

Each liposomal formulation was analyzed at six different concentrations. The spun down liposomes were resuspended by shaking the cells and re-analyzed, leading to an identical result, indicating stability. Experiments were performed for six different liposome concentrations per formulation in one replicate for each liposomal formulation.



Appendix Figure S3: Effects of targeted AS605240 delivery on the inflammatory response.

(A) Pro-inflammatory-cytokines essential for the host defence were analyzed in EDTA-plasma from PCI and sham animals. #p<0.05 against sham, *p<0.05 as indicated; Kruskal-Wallis ANOVA with controlled false-discovery rates (Benjamini-Hochberg procedure). The p-values are given in Appendix Table S3.
(B) Cytokine profiles are depicted in a self-organizing heat-map according to their similarity of appearance in plasma. Information on replicates can be found in Figures 3 B and 3 C).



Appendix Figure S4: Scheme on processing and analysis of multispectral optoacoustic tomography (MSOT) images for the quantification of liver function by indocyanine green (ICG) clearance.

MSOT imaging is performed to derive time-resolved cross-sectional images of liver tissue and ICG distribution. MSOT image stacks are first pre-processed to normalize ICG intensity values and smooth time course data. The time derivatives of pixel intensities within a region of interest (ROI) from one-time frame to the next serve as input for pixel-wise kinetic clustering. By applying k-means clustering with k set to 4, 4 main kinetic curves (cluster centers) present in the ROI are extracted, and color-coded images are generated to visualize the spatial distribution of those clusters for each animal. For quantification of ICG signal, only those cluster centers reflecting signal net increase are taken into account and combined into one curve, incorporating the respective abundances of pixels for each animal individually. All known three phases of ICG pharmacokinetics are clearly evident in those curves: first-pass (peak), re-distribution (exponential decay) and the final linear phase representing the dyeclearance through the liver. The area under the curve (AUC) was calculated from the linear decay phase to estimate the elimination capacity of the liver.



Appendix Figure S5: Effects of the non-targeted liposomal AS605240 formulation on survival in the peritoneal contamination and infection (PCI) sepsis model.

Group sizes for sham groups NT-Lipo: 6 (50% female), NT-LipoAS: 2 (50% female) animals. For PCI (sepsis) groups: Veh: 25 (56% female), NT-Lipo: 12 (50% female), NT-LipoAS: 12 (50% female) animals. The survival is monitored for seven days in this model. In the first two or three days, the acute phase had passed and increasingly processes related to a cornification occur. Animals appear phenotypically healthy after five to seven days. However, it is common in this model for abscesses to occur without visible symptoms, which in some cases may even be macroscopically detected as early as 24 h post-infection, due to the lack of a surgical intervention cleaning and disinfecting the primary site of infection (here: abdominal cavity). These abscesses may grow and eventually rupture, causing spontaneous death unrelated to the actual experiment. As a consequence, the survival is limited here to seven days. The p-values of the statistical analysis are provided in Appendix Table S3.



Appendix Figure S6: Gating of Lavage cells for analysis.

Gating was performed as previously described by Watson et al. (J Immunol. 2016, 194(6): 2796-2809, PMID: 25681345). Peritoneal lavage and subsequent processing and staining were carried out as described in the method section. The figure depicts the gating strategy. A stained (pink) and unstained (black/grey) sample is overlaid in the XY-Plots: (**A**) Forward scatter vs side scatter plot with gate R0 to separate cell events from debris. (**B**) Fluorescence labeled double-positive CD11b+ CD45+ cells are then gated (R1) from R0. (**C**) CD115- and Ly-6c negative fraction of R1 is depicted, and R2 gate is used to count cells neutrophils. CD115+, Ly6c+ cells (#R1-#R2, with # stands for the number of cells in each gate) are classified as monocytes. Data are normalized to the volume used for measurement, obtaining the concentration of cells per volume lavage.

Appendix Table S1: PI3Kγ expression in human tissue biopsies.LSECs: liver sinusoidal endothelial cells, KCs: Kupffer cells (local macrophages)Sample informationPI3Kγ expression

Sample Inform	ation			ΡΙ3Κγ εχ	pression	
Diagnosis	Gender	N	Hepatocytes	LSECs, KCs	Infiltrating immune cells	endothelial cells of larger vasculature
Non-alcoholic fatty liver disease (NASH)	female male	3 1	yes	no	Yes	yes
Autoimmune hepatitis (AIH)	male female	1 1	yes	no	Yes	yes
Liver cirrhosis	female male	2	yes	no	Yes	yes

Parameter	huHEP 🖧 DP20	huHEP ♀ _{DP20}
Number of Donors	20	20
Donor Age Average	36.9	41.1
Donor BMI Average ^a	26.3	29.2
Male Donors	100.0%	0.0%
Female Donors	0.0%	100.0%
Asian Donors	5.0%	0.0%
Afro American Donors	5.0%	10.0%
Caucasian Donors	80%	85.0%
Other Donors	10.0%	5.0%
No Drugs/ Alcohol/ Tobaco	45.0%	60.0%
Illicit Drug use	35.0%	20.0%
Tobacco Use	35.0%	20.0%
Heavy alcohol use ^b	5.0%	5.0%
Serologies CMV	Positive	Positive
Serologies EBV	Positive	Positive
Serologies HBV	Negative	Negative
Serologies HCV	Negative	Negative
Serologies HIV	Negative	Negative
CYP1A2 (pmol/ 10 ⁶ cells/min, 100 µmol L ⁻¹ Phenacetin)	68.7	81.7
OATP1B1/3 Active Estrone-3-S Uptake (pmol/ 10 ⁶ cells/min, 10 µmol L ⁻¹ Estrone-3-S) ^c	1.6	1.9
NTCP Active Taurocholate Uptake (pmol/ 10 ⁶ cells/min, 10 µmol L ⁻¹ Taurocholate) ^c	2.9	3.5

Appendix Table S2: Characterization of primary human hepatocyte donor pools (Lonza, Switzerland).

^a Body mass index (BMI) is derived from body mass (weight) divided by the square of the body height of a person.

^b Heavy Alcohol use is defined as >2 drinks per day or current history of alcoholism

^c Transporter Activity is the amount of specific substrate retained on hepatocytes after incubation with 10 μmol L⁻¹ substrates at 4°C or at 37°C for 3 min. Active uptake is the fold change between uptake at 37°C versus 4°C. The uptake is expressed in pmol per 10⁶ cells per min.

Appendix Table S3: p-Value Tables for Figures 2 to 5 in the main manuscript and Appendix Figure S3 and S5

	Figure 2 E	AS605240 guantifica	tion							
	Tissue	p-value	w							
N	Lung	0,00729	0							
2	Spleen	0.00729	0							
n	Liver	0 2207	5							
i.	Kidnev	0.01351	0							
	Fat	0.00729	0							
	Brain	0,00720	10							
	Dialit	1	10							
	Figure 3 B	Interleukin 6 (IL-6)								
	p-value table	sham	PCI Vehicle	PCI T-Lipo	PCI AS					
	PCIVehicle	2 1E-05								
	PCIT-Lino	5 3E-05	1.0E+00							
	DCI AS	9.1E-06	1 3E-01	1.4E-01						
	PCI T Line AS	5,12,00	1,00-01	1,40-01	2.55.02					
	РСПТ-Црона	5,5E-05	1,4⊏-01	1,02-02	2,51-05					
	Finues 2 D	Interlevilie d hete (II	40)							
	Figure 3 B	Interleukin 1 beta (IL	-16)							
	p-value table	snam	PCI Venicle	РСІ І-Ціро	PCLAS					
	PCI Vehicle	2,31E-02								
	PCI T-Lipo	6,16E-01	0,0231							
	PCIAS	1,07E-02	0,6162	0,0107						
	PCI T-LipoAS	7,80E-02	0,0014	0,4255	0,0014					
	Figure 3 B	I umor Necrosis Fac	tor alpha (INF-α)						
	p-value table	sham	PCI Vehicle	PCI T-Lipo	PCIAS					
	PCI Vehicle	2,40E-05								
	PCI T-Lipo	3,70E-05	0,61407							
	PCIAS	3,40E-06	0,01025	0,03152						
	PCI T-LipoAS	4,15E-03	0,00141	0,00052	0,0001					
	Figure 3 B	Interferon gamma (IF	Ν-γ)							
	p-value table	sham	PCI Vehicle	PCI T-Lipo	PCI AS					
	PCI Vehicle	0,0140								
	PCI T-Lipo	0,0000	1,0000							
	PCI AS	0,0017	0,3563	0,3563						
	PCI T-LipoAS	0,0140	1,0000	1,0000	0,3563					
	Figure 3 B	Macrophage chemo	tactic protein 1 (I	NCP-1)						
	p-value table	sham	PCI Vehicle	PCI T-Lipo	PCI AS					
	PCI Vehicle	1,70E-05								
	PCI T-Lipo	3,00E-05	0,58064							
	PCIAS	4,70E-06	0,0492	0,06094						
	PCI T-LipoAS	7,20E-05	0,14442	0,01105	0,00033					
	Figure 3 C	Interleukin 10 (IL-10)								
	p-value table	sham	PCI Vehicle	PCI T-Lipo	PCI AS					
	PCI Vehicle	6,96E-01								
	PCI T-Lipo	2,80E-02	0,1107							
	PCIAS	7,30E-03	0,0382	0,554						
	PCI T-LipoAS	9,39E-01	0,6858	0,0143	0,0073					
		Berte del Bronder							1	
	Figure 3 D	Bacterial Burden	Lavage						10.101	
	p-value table	PCI_AS_24h	PCI_AS_48h	sham_24h	sham_48h	I-Lipo_24n I	-Lipo_48n I-Lip	oAS_24n I-Lip	DAS_48n ven	icle_24n
	PCI_AS_48h	0,0227								
	sham_24h	0,0094	0,0094							
	sham_48h	0,0094	0,0094	0,4526						
	T-Lipo_24h	0,0157	0,8081	0,0190	0,2350					
	T-Lipo_48h	0,0097	0,1584	0,0190	0,2350	0,4526				
	T-LipoAS_24h	0,0094	0,6724	0,0094	0,0097	0,8081	0,3833			
3	T-LipoAS_48h	0,0097	0,0808	0,0190	0,2350	0,2647	0,5464	0,1169		
- S	vehicle_24h	0,0175	0,1286	0,0094	0,0094	0,3360	0,8081	0,2493	0,3360	0.4050
Fig	vehicle_48h	0,0079	0,0094	0,0094	0,0097	0,0420	0,1324	0,0175	0,6948	0,1853
	Figure 3 E	Bacterial Burden	Liver							
	p-value table	PCI AS 24h	PCI AS 48h	sham 24h	sham 48h	T-Lipo 24h 1	-Lipo 48h T-Lip	oAS 24h T-Lip	AS 48h veh	icle 24h
	PCI AS 48h	0.0384		_	-				-	_
	sham 24h	0.0095	0.0095							
	sham 48h	0.0103	0.0103	0.0766						
	T-Lipo 24h	0.0521	0 9545	0.0103	0.025					
	T-l ino 48h	0,0021	0,0040	0,0103	0,025	0.0450				
	T-Lipoon	0,0100 0 000	0,0400	0,0100	0,020	0,0409	0.025			
	T-LipoAS 4%	0,0200	0,0092	0,0090	0,0103	0,0012	0.7526	0 1444		
	r-LipuAo_460	0,0157	0,992	0,0103	0,025	0,20	0,7320	0.0551	0 1074	
	vehicle_240	0,025	0,7724	0,0095	0,0103	0,0073	0,0727	0,9551	0,1974	0.0414
	* emole_+011	0,0107	0,023	0,0090	0,0105	0,0332	0,0001	0,0004	0,0124	5,0414
	Figure 3 F	Neutrophils	24 h							
	p-value table	sham	PCI vehicle	PCI T-Lipo	PCI AS		-			
	PCI vehicle	0,36								
	PCI T-Lipo	0,36	0,77							
	PCIAS	0,77	0,53	0,36						
	PCI T-LipoAS	0,82	0,77	0,77	0,77					

	Figure 3 F	Neutrophils	48 h							
	n-value table	sham	PCI vehicle	PCI T-Lino	PCLAS					
	PCI vehicle	0.37	Porvenicie	ГСПТЕРО	I OTAS					
	PCI T-L ino	0,07	0.24							
		0,17	0,24	0.31						
	PCI AS	40	0,00	0,31	0.49					
	P OI 1-EIDOAD	0,01	0,00	0,55	0,40					
	Figure 3 G	Monocytes	24 h							
	p-value table	sham	PCI vehicle	PCI T-Lipo	PCIAS					
	PCI vehicle	0,925								
	PCI T-Lipo	0,059	0,610	0.004						
	PCIAS	0,925	0,950	0,881						
	PCIT-LipoAS	0,881	0,950	0,940	1,000					
	Figure 3 G	Monocytes	48 h							
	p-value table	sham	PCI vehicle	PCI T-Lipo	PCI AS					
	PCI vehicle	0,77								
	PCI T-Lipo	0,147	0,025							
	PCI AS	0,788	0,147	0,147						
	PCIT-LipoAS	0,788	0,788	0,147	0,788					
	Figure 3 H	PMN positive cells								
	p-value table	PCI_AS_24h	PCI_AS_48h	sham_24h	sham_48h	T-Lipo_24h	T-Lipo_48h	T-LipoAS_24h	T-LipoAS_48h	vehicle_24h
	PCI_AS_48h	0,0424							_	
	sham_24h	1	0,016							
	sham_48h	0,2721	0,2249	0,2249						
	T-Lipo_24h	0,0336	0,1088	0,0176	0,0722					
	T-Lipo_48h	0,0424	0,0714	0,0336	0,0536	0,9144				
	T-LipoAS_24h	0,0189	0,2278	0,0094	0,0542	0,6797	0,9144			
	T-LipoAS_48h	0,0336	1	0,009	0,2063	0,1785	0,1826	0,2249	1	
	sham	0,2249	0,0039	0,2249	0,0747	0,009	0,0176	0,0014	, 0,001	14
	Figure 4C	AUC indocyanine gr	een clearance							
e 4	p-value table	PCI LipoAS	PCI Vehicle	sham LipoAS						
'n	PCI Vehicle	1,20E-06								
Ĕ	sham LipoAS	1,40E-05	2,40E-05							
	sham Vehicle	0,11	1,40E-05	9,90E-05						
	Figure 5 B	Suprival								
	rigure 5 B	BCI Vehicle	DCI AS	cham Vahiola						
	PCLAS	0 28622		Shann vehicle						
	sham Vahicla	0,20022	0.00072							
	sham AS	0.00072	0.00411	1						
е 2										
ň										
Ĕ	Figure 5 C	Survival								
	p-value table	PCI Vehicle	PCI T- Lipo	PCI T-LipoAS	sham T-LipoAS					
	PCI T-Lipo	0,9135								
	PCI T-LipoAS	0,0053	0,0053							
	sham T-LipoAS	0,0028	0,003	0,0561						
	snam i -Lipo	0,0103	0,0144	0,1479	1					
	Appendix Figure S3	Interferon 1 beta (IFN	Ι-1β)							
	p-value table	sham	PCI Vehicle	PCI T-Lipo	PCI AS					
	PCI Vehicle	1,60E-03								
	PCI T-Lipo	2,89E-02	0,2542							
	PCIAS	2,89E-02	2,89E-02	0,847						
	PCI I-LIPOAS	7,50E-03	0,0674	0,8672	0,9049					
e v	Appendix Figure S3	Interferon 1 beta (IFN	I-1B)							
n	p-value table	sham	PCI Vehicle	PCI T-Lipo	PCI AS					
ιĔ	PCI Vehicle	1,70E-02								
, Xi	PCI T-Lipo	1,99E-01	0,335							
ē	PCI AS	3,60E-01	0,039	0,379						
d	PCI T-LipoAS	3,60E-01	0,039	0,335	0,929					
٩										
	Appendix Figure S3	Interleukin 1 alnha (li	-1a)							
	p-value table	sham	PCI Vehicle	PCI T-Lipo	PCI AS					
	PCI Vehicle	2,00E-02								
	PCI T-Lipo	1,81E-01	0,045							
	PCI AS	4,58E-01	0,055	0,807						
	PCI T-LipoAS	1,00E-02	4,58E-01	0,04	0,036					
	Annendia Firmer CT	Committee l								
×ю	Appendix Figure S5	Survival PCI Vehicle	PCI Linc	PCI Line AS	sham Linc					
) S		∩ 730	гогцро	r or LipuAo	anam Lipo					
<u>ہ</u> د		0,702								

= 0	p-value table	FOI VEIIICIE	гогшро	гогыроло	sham Lipo
e e	PCI Lipo	0,732			
a ng	PCI LipoAS	0,1764	0,2361		
₹i£	sham Lipo	0,0014	0,0106	0,0014	
	sham LipoAS	0,0888	0,1764	0,0888	1